To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
Clinical trial NCT05223686 · UNKNOWN
Trial details
- NCT number
- NCT05223686
- Sponsor
- Hrain Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-10
- Primary completion
- 2023-06-10
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.